{"id":"https://openalex.org/W2118186702","doi":"https://doi.org/10.1111/j.1463-1326.2009.01046.x","title":"Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase\u20104 inhibitor in male type 2 diabetes patients","display_name":"Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase\u20104 inhibitor in male type 2 diabetes patients","alternate_titles":[],"publication_year":2009,"publication_date":"2009-05-19","ids":{"openalex":"https://openalex.org/W2118186702","doi":"https://doi.org/10.1111/j.1463-1326.2009.01046.x","mag":"2118186702","pmid":"https://pubmed.ncbi.nlm.nih.gov/19476474"},"language":"en","primary_location":{"id":"doi:10.1111/j.1463-1326.2009.01046.x","doi":"https://doi.org/10.1111/j.1463-1326.2009.01046.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2009.01046.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2118186702"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065775242","display_name":"Tim Heise","orcid":"https://orcid.org/0000-0002-8346-2037","observed_orcids":["https://orcid.org/0000-0002-8346-2037"]},"institutions":[{"id":"https://openalex.org/I4210165534","display_name":"Profil Institute for Metabolic Research","ror":"https://ror.org/05krxy197","country_code":"DE","type":"facility","lineage":["https://openalex.org/I4210165534"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"T. Heise","raw_affiliation_strings":["Profil Institut f\u00fcr Stoffwechselforschung GmbH, Hellersbergstrasse, Neuss, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Profil Institut f\u00fcr Stoffwechselforschung GmbH, Hellersbergstrasse, Neuss, Germany","institution_ids":["https://openalex.org/I4210165534"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062930194","display_name":"Eva U. Graefe-Mody","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"E. U. Graefe\u2010Mody","raw_affiliation_strings":["Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071240753","display_name":"Silke H\u00fcttner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"S. H\u00fcttner","raw_affiliation_strings":["Department of Clinical Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050453842","display_name":"Arne Ring","orcid":"https://orcid.org/0000-0002-4324-5820","observed_orcids":["https://orcid.org/0000-0002-4324-5820"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"A. Ring","raw_affiliation_strings":["Department of Medical Data Services, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Data Services, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038949703","display_name":"Dirk Trommeshauser","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"D. Trommeshauser","raw_affiliation_strings":["Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111521277","display_name":"Klaus A. Dugi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"K. A. Dugi","raw_affiliation_strings":["Corporate Department Medical Affairs, Boehringer Ingelheim GmbH, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Corporate Department Medical Affairs, Boehringer Ingelheim GmbH, Ingelheim, Germany","institution_ids":["https://openalex.org/I1330995197"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":null,"fwci":16.6088,"has_fulltext":false,"cited_by_count":193,"citation_normalized_percentile":{"value":0.99512358,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"11","issue":"8","first_page":"786","last_page":"794"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11140","display_name":"Natural Antidiabetic Agents Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/linagliptin","display_name":"linagliptin","score":1.0},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.9509999752044678},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9829999804496765},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9900000095367432},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9929999709129333},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.7440000176429749},{"id":"https://openalex.org/keywords/dpp-4-inhibition","display_name":"DPP-4 inhibition","score":0.8119999766349792},{"id":"https://openalex.org/keywords/oral-glucose-tolerance","display_name":"oral glucose tolerance","score":0.6610000133514404},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.8169999718666077},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.7850000262260437},{"id":"https://openalex.org/keywords/male-patients","display_name":"male patients","score":0.628000020980835}],"concepts":[{"id":"https://openalex.org/C2780031085","wikidata":"https://www.wikidata.org/wiki/Q909745","display_name":"Linagliptin","level":4,"score":0.9972051382064819},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8676466345787048},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7361891269683838},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7256873846054077},{"id":"https://openalex.org/C2778763485","wikidata":"https://www.wikidata.org/wiki/Q419770","display_name":"Dipeptidyl peptidase-4 inhibitor","level":4,"score":0.7187384366989136},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7065962553024292},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6538712978363037},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.6013635993003845},{"id":"https://openalex.org/C156490143","wikidata":"https://www.wikidata.org/wiki/Q412214","display_name":"Dipeptidyl peptidase-4","level":4,"score":0.5550158023834229},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5476096272468567},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5019798278808594},{"id":"https://openalex.org/C2776453732","wikidata":"https://www.wikidata.org/wiki/Q421042","display_name":"Vildagliptin","level":4,"score":0.4897191822528839},{"id":"https://openalex.org/C2781469919","wikidata":"https://www.wikidata.org/wiki/Q5279728","display_name":"Dipeptidyl peptidase","level":3,"score":0.45774927735328674},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.45119214057922363},{"id":"https://openalex.org/C76318530","wikidata":"https://www.wikidata.org/wiki/Q16833590","display_name":"Area under the curve","level":2,"score":0.41930609941482544},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4136529564857483},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3333553075790405},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.14693236351013184},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.046850115060806274},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000069476","descriptor_name":"Linagliptin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008657","descriptor_name":"Metabolic Clearance Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D018819","descriptor_name":"Dipeptidyl Peptidase 4","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1463-1326.2009.01046.x","doi":"https://doi.org/10.1111/j.1463-1326.2009.01046.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2009.01046.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:19476474","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19476474","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320321091","display_name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","ror":"https://ror.org/00x0ma614"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":35,"referenced_works":["https://openalex.org/W1977529484","https://openalex.org/W1977619586","https://openalex.org/W1978297909","https://openalex.org/W1980937864","https://openalex.org/W1982778753","https://openalex.org/W1984635769","https://openalex.org/W1986044732","https://openalex.org/W1986085856","https://openalex.org/W1989963909","https://openalex.org/W1991565451","https://openalex.org/W1993270448","https://openalex.org/W1994743271","https://openalex.org/W1999917583","https://openalex.org/W2001739257","https://openalex.org/W2011238752","https://openalex.org/W2018192866","https://openalex.org/W2028648326","https://openalex.org/W2033198459","https://openalex.org/W2036167841","https://openalex.org/W2038445107","https://openalex.org/W2043121816","https://openalex.org/W2048689701","https://openalex.org/W2054185381","https://openalex.org/W2063976195","https://openalex.org/W2069150029","https://openalex.org/W2084403835","https://openalex.org/W2085862152","https://openalex.org/W2093303670","https://openalex.org/W2101405557","https://openalex.org/W2108771199","https://openalex.org/W2112228502","https://openalex.org/W2123629330","https://openalex.org/W2145266416","https://openalex.org/W2156150085","https://openalex.org/W2171512247"],"related_works":["https://openalex.org/W2150641192","https://openalex.org/W2068691394","https://openalex.org/W2042822582","https://openalex.org/W2062945641","https://openalex.org/W2331319476","https://openalex.org/W2068745223","https://openalex.org/W2146937127","https://openalex.org/W2062383561","https://openalex.org/W1991670435","https://openalex.org/W197891819"],"abstract_inverted_index":{"AIMS:":[0],"To":[1],"investigate":[2],"the":[3,15,57,135,157,233,239,245],"safety,":[4],"tolerability,":[5],"pharmacokinetic":[6],"and":[7,61,87,172,202,223],"pharmacodynamic":[8],"properties":[9],"of":[10,14,82,103,119,163,185,205,218,228,242],"multiple":[11,215],"oral":[12,150],"doses":[13,217],"dipeptidyl":[16],"peptidase-4":[17],"(DPP-4)":[18],"inhibitor":[19,247],"linagliptin":[20,38,126,169,193,219,243],"(BI":[21],"1356)":[22],"in":[23,79,114,130,134,225,244],"patients":[24,36],"with":[25,70,125,168,177,192,196,232],"type":[26,33,211],"2":[27,34,212],"diabetes":[28],"mellitus.":[29],"METHODS:":[30],"Forty-seven":[31],"male":[32],"diabetic":[35,213],"received":[37],"1,":[39],"2.5,":[40],"5":[41,171],"or":[42,45],"10":[43,173],"mg,":[44],"placebo,":[46],"once":[47],"daily":[48],"for":[49],"12":[50],"days.":[51],"RESULTS:":[52],"Linagliptin":[53,179],"exposure":[54],"[area":[55],"under":[56],"plasma":[58,63,120,127],"concentration-time":[59],"curve":[60],"maximum":[62],"concentration":[64],"(Cmax)]":[65],"increased":[66],"less":[67],"than":[68,195],"proportionally":[69],"dose.":[71],"Accumulation":[72],"half-life":[73,95],"was":[74,108,146,180,189],"short":[75],"(8.6-23.9":[76],"h),":[77],"resulting":[78,129],"rapid":[80],"attainment":[81],"steady":[83],"state":[84],"(2-5":[85],"days)":[86],"little":[88],"accumulation":[89],"(range:":[90],"1.18-2.03).":[91],"The":[92,183],"long":[93],"terminal":[94],"(113-131":[96],"h)":[97],"led":[98],"to":[99],"a":[100],"sustained":[101],"inhibition":[102,132,145],"DPP-4":[104,121,131,144,246],"activity.":[105],"Renal":[106],"excretion":[107],"below":[109],"1%":[110],"on":[111],"day":[112],"1":[113],"all":[115],"dose":[116,138],"groups.":[117],"Inhibition":[118],"activity":[122],"correlated":[123],"well":[124,181,221],"concentrations,":[128],">90%":[133],"two":[136],"highest":[137],"groups;":[139],"even":[140],"24":[141,154],"h":[142,155],"postdose,":[143],">80%.":[147],"Following":[148],"an":[149],"glucose":[151,164,229],"tolerance":[152],"test,":[153],"after":[156],"last":[158],"dose,":[159],"statistically":[160],"significant":[161,226],"reductions":[162],"excursions":[165],"were":[166,207,220],"observed":[167],"(2.5,":[170],"mg":[174],"doses)":[175],"compared":[176],"placebo.":[178],"tolerated.":[182],"frequency":[184],"adverse":[186],"events":[187],"(AEs)":[188],"not":[190],"higher":[191],"(54%)":[194],"placebo":[197],"(75%).":[198],"No":[199],"serious":[200],"AEs":[201],"no":[203],"episodes":[204],"hypoglycaemia":[206],"reported.":[208],"CONCLUSIONS:":[209],"In":[210],"patients,":[214],"rising":[216],"tolerated":[222],"resulted":[224],"improvements":[227],"parameters.":[230],"Together":[231],"favourable":[234],"pharmacokinetics,":[235],"these":[236],"results":[237],"confirm":[238],"unique":[240],"profile":[241],"class.":[248]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2118186702","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":10},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":10},{"year":2015,"cited_by_count":10},{"year":2014,"cited_by_count":11},{"year":2013,"cited_by_count":19},{"year":2012,"cited_by_count":33}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
